Dermapharm Holding SE : Q2 prelims due 23 Aug – Forecasting a weaker quarter
>Revenues, adj. EBITDA to be down y-o-y - After a strong Q1, driven by strong revenues from the collaboration with BioNTech, which drove adj. EBITDA up by c. 18% y-o-y in the quarter (revenues c. +9% y-o-y), we forecast a weaker Q2 with revenues to be up by just c. 6% y-o-y and adj. EBITDA to be even down by c. 4% y-o-y. The core reason is branded pharmaceuticals, for which we estimate a 1% y-o-y decline in revenues (to € 140m) and a 9% y-o-y decline in adj. EBITDA in...Dermapharm Holding SE. Dermapharm Holding SE is a Germany-based company engaged in manufacturing of patent-free branded pharmaceuticals. The Company operates through two segments: Branded pharmaceuticals and other healthcare products, which includes in-house development, in-house production, and distribution of branded pharmaceuticals and other healthcare products, and Parallel import business, which operates under the axicorp brand. It holds around 950 marketing authorizations for more than 250 active pharmaceutical ingredients, which are marketed as pharmaceuticals, dietary supplements or supplemental balanced diets. The Company offers its products through a number of brands, including Dekristol, Ampho Moronal, Keltican, Tromcardin, among others. It is active primarily in Germany, Switzerland and Austria. Additionally, it operates production facility in Germany. Trommsdorff & GmbH Co KG is a subsidiary of the Company.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.